Mexico Constipation Therapeutics Market Analysis

Mexico Constipation Therapeutics Market Executive Summary

Mexico Constipation Therapeutics Market was valued at $273 Mn in 2022 and is estimated to reach $460 Mn in 2030, exhibiting a CAGR of 6.75% during the forecast period.

Constipation is a digestive condition characterized by irregular bowel movements, difficulty in stool passage, or the discharge of hard and dry stool. This condition arises when the transit of stool through the colon (large intestine) slows down, resulting in increased water absorption and stool hardening. Typical symptoms of constipation include straining during bowel movements, a feeling of incomplete evacuation, abdominal discomfort, and irregular or infrequent bowel habits. Multiple factors, such as a low-fiber diet, insufficient fluid intake, lack of physical activity, specific medications, and underlying medical issues, can contribute to constipation. Addressing constipation often involves lifestyle modifications, dietary changes, increased physical activity, and, when necessary, the use of medications to manage and alleviate symptoms.

Constipation prevalence ranges from 2.4% to 22.3% in Mexico, with an average of 14.4%. Constipation affects women more frequently than it does men. There may be potential peaks in the prevalence of certain population groups, such as children and adults over 65. Furthermore, there are higher rates of constipation in rural areas than in urban areas, which could be associated with factors like dietary variations or restricted access to healthcare.

In the realm of constipation therapeutics, promising advancements are being made through the targeting of specific receptors. Clinical trials indicate the potential efficacy of drugs focusing on guanylate cyclase C (GC-C) and serotonin 4 (5-HT4) receptors. These targeted approaches aim to enhance gastrointestinal function and alleviate constipation symptoms. Moreover, ongoing research is delving into innovative targets such as bile acid signaling and modulation of the enteric nervous system. The exploration of these novel avenues underscores a dynamic and evolving landscape in the development of constipation treatments, offering potential breakthroughs in addressing underlying causes and improving patient outcomes.

Market Dynamics

Market Growth Drivers

Increase in Elderly Population: The growing elderly population in Mexico is a significant driver for the constipation therapeutics market. As people age, they are more prone to constipation, leading to a higher demand for constipation treatment. According to a report, more than half of individuals over 50 are susceptible to persistent constipation, and constipation affects roughly 16% of adults worldwide, with a higher prevalence in the elderly.

Changing Dietary Habits and Sedentary Lifestyles: The changing dietary habits and sedentary lifestyles in Mexico have contributed to an increased demand for constipation treatment. Factors such as insufficient consumption of fast food, low fiber intake, and reduced physical activity have been associated with constipation. The COVID-19 pandemic and the associated lockdown measures have also led to the development of new-onset constipation symptoms, highlighting the impact of lifestyle changes on digestive health.

Improvements in Healthcare Infrastructure: The improvements in healthcare infrastructure in Mexico have led to better diagnosis and treatment of constipation, contributing to market growth. The presence of healthcare professionals, the high prevalence of irritable bowel syndrome (IBS) and chronic constipation, and the development of advanced drugs and treatment procedures have revolutionized the constipation treatment market.

Market Restraints

Regulatory Environment: The regulatory environment presents challenges for the constipation therapeutics market. The prolonged and costly process of obtaining approval for new medications delays their market availability while navigating intricate reimbursement procedures can impede access for both healthcare institutions and patients. This regulatory landscape acts as a significant restraint, affecting the timely introduction and accessibility of specific constipation medications in the market.

Cost and Affordability: Cost and affordability pose significant challenges for the constipation therapeutics market. The high expenses associated with newer medications limit accessibility, particularly for those lacking comprehensive insurance coverage. Unequal access to healthcare, especially in rural areas, exacerbates the issue, hindering timely diagnosis and treatment of constipation. Additionally, even with insurance, elevated out-of-pocket costs for specific medications or laxatives act as barriers for some patients, impacting market penetration and growth.

Sociocultural Factors: Sociocultural factors, including constipation stigma and reliance on traditional remedies, pose a significant restraint on the constipation therapeutics market. The stigma leads to hesitancy in seeking medical assistance, while the preference for traditional remedies can cause delays in proper diagnosis and treatment. Overcoming these barriers requires tailored educational initiatives and the development of therapeutics aligned with local practices to enhance their effectiveness in the market.

Healthcare Policies and Regulatory Landscape

In Mexico, the oversight of healthcare policies and regulatory control over therapeutic drugs primarily falls under the Federal Committee for Protection against Sanitary Risk (COFEPRIS), a branch of the Ministry of Health. COFEPRIS collaborates with the Ministry of Health to ensure the effectiveness, safety, and quality of medications. The National Cancer Institute (INCan) serves as a key reference organization for cancer care, and the National Institute of Public Health (INSP) contributes to the scientific foundation for healthcare decisions. The Mexican Social Security Institute (IMSS) plays a role in influencing drug accessibility and usage regulations for insured individuals, while the General Health Council provides advisory services on health-related matters. Additionally, the National Commission for Protection against Health Risks (CONARIS) facilitates risk evaluation and management.

Competitive Landscape

Key Players

• AbbVie
• Allergan
• Boehringer Ingelheim
• EMS
• Farmoquímica
• Grünenthal
• Johnson & Johnson
• Norgine
• Pfizer
• Sanofi